Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | PPARD | Q03181 | 2/20 | 0.45 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.42 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.42 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL212642 | 0.98 | TSHR (0.54) | TSHRCYP3A4PPARDLPAR3LPAR1 | |
| SCHEMBL28589893 | 0.98 | TSHR (0.54) | TSHRCYP3A4PPARDLPAR3LPAR1 | |
| SCHEMBL28651252 | 0.93 | TSHR (0.59) | TSHRCYP3A4PPARDLPAR3LPAR1 | |
| SCHEMBL11858608 | 0.89 | CYP3A4 (0.52) | TSHRCYP3A4PPARDLPAR3LPAR1 | |
| SCHEMBL342779 | 0.89 | TSHR (0.72) | TSHRCYP3A4LPAR3LPAR1LPAR2 | |
| SCHEMBL12658607 | 0.88 | TSHR (0.43) | TSHRCYP3A4PPARDLPAR3LPAR1 | |
| SCHEMBL29759432 | 0.86 | CYP3A4 (0.50) | TSHRCYP3A4LPAR3LPAR1LPAR2 | |
| SCHEMBL21122056 | 0.86 | CYP3A4 (0.50) | TSHRCYP3A4LPAR3LPAR1LPAR2 | |
| SCHEMBL11849399 | 0.86 | CYP3A4 (0.50) | TSHRCYP3A4LPAR3LPAR1LPAR2 | |
| SCHEMBL27042152 | 0.86 | TSHR (0.68) | TSHRCYP3A4LPAR3LPAR1LPAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160264593-A1 | PROTEIN PHOSPHATASE INHIBITORS THAT CROSS THE BLOOD BRAIN BARRIER | LIXTE BIOTECHNOLOGY, INC. | 2016-09-15 | — | — | US | disclosed |
| US-8329914-B2 | Cyclic benzimidazole derivatives useful as anti-diabetic agents | MERCK SHARP & DOHME CORP (US) | 2012-12-11 | — | — | US | disclosed |
| US-20110218174-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME CORP. (US) | 2011-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264593-A1 | PROTEIN PHOSPHATASE INHIBITORS THAT CROSS THE BLOOD BRAIN BARRIER | DUSP1, PPP5C, DUSP15 | TSHR 4502/4885CYP3A4 3368/4885PPARD 4161/4885 |
| US-20110218174-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | PRKAG2, PRKAG1, PRKAB2 | TSHR 3412/4885CYP3A4 2052/4885PPARD 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.